目的 探討心腦聯(lián)通膠囊聯(lián)合鹽酸阿羅洛爾片治療不穩(wěn)定型心絞痛的臨床療效。方法 選擇2020年3月—2021年3月在長(zhǎng)安醫(yī)院治療的172例不穩(wěn)定型心絞痛患者，根據(jù)用藥的差別分為對(duì)照組和治療組，每組各86例。對(duì)照組口服鹽酸阿羅洛爾片，10 mg/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服心腦聯(lián)通膠囊，2 g/次，3次/d。兩組均經(jīng)40 d治療。觀察兩組患者臨床療效和心電圖療效，比較治療前后兩組患者心絞痛情況，心功能，血清學(xué)指標(biāo)堿性成纖維生長(zhǎng)因子（bFGF）、血管性血友病因子（vWF）、α顆粒膜蛋白（GMP-140）、組織金屬蛋白酶抑制因子1（TIMP1）和轉(zhuǎn)化生長(zhǎng)因子β結(jié)合蛋白2（LTBP2）水平。結(jié)果 經(jīng)治療，治療組臨床有效率明顯高于對(duì)照組（98.84% vs 86.05%，P<0.05）。經(jīng)治療，治療組心電圖療效明顯高于對(duì)照組（98.84% vs 87.21%，P<0.05）。經(jīng)治療，兩組心絞痛發(fā)作次數(shù)、持續(xù)時(shí)間、硝酸甘油消耗量均顯著減少（P<0.05），且治療組更明顯（P<0.05）。經(jīng)治療，兩組患者內(nèi)皮依賴(lài)性血管舒張功能（FDM）和左心室射血分?jǐn)?shù)（LVEF）明顯升高，而左室收縮末期內(nèi)徑（LVESD）和左室舒張末期內(nèi)徑（LVEDD）明顯下降（P<0.05），且治療組心功能明顯好于對(duì)照組（P<0.05）。經(jīng)治療，兩組患者血清bFGF、GMP-140和TIMP-1水平明顯升高，而vWF和LTBP-2水平明顯降低（P<0.05），且治療組患者血清指標(biāo)水平明顯好于對(duì)照組（P<0.05）。結(jié)論 心腦聯(lián)通膠囊聯(lián)合鹽酸阿羅洛爾片治療不穩(wěn)定型心絞痛患者不僅促進(jìn)癥狀改善，還能夠促進(jìn)機(jī)體細(xì)胞因子及心功能的改善，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Xinnao Liantong Capsules combined with arolol in treatment of unstable angina pectoris. Methods Patients (172 cases) with unstable angina pectoris in Chang'an Hospital from March 2020 to March 2021 were divided into control and treatment group according to different treatments, and each group had 86 cases. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 10 mg/time, twice daily. Patients in the treatment group were po administered with Xinnao Liantong Capsules on the basis of the control group, 2 g/time, three times daily. Patients in two groups were treated for 40 d. After treatment, the clinical evaluation and ECG effects were evaluated, the state of angina, cardiac function, the levels of serological indexes bFGF, GMP-140, TIMP-1, vWF and LTBP-2 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (98.84% vs 86.05%, P < 0.05). After treatment, the curative effect of ECG in the treatment group was significantly higher than that in the control group (98.84% vs 87.21%, P < 0.05). After treatment, the frequency, duration and nitroglycerin consumption of angina pectoris in two groups were significantly reduced (P < 0.05), especially in the treatment group (P < 0.05). After treatment, FDM and LVEF were significantly increased, while LVESD and LVEDD were significantly decreased in two groups (P < 0.05), and the cardiac function in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of serum bFGF, GMP-140 and TIMP-1 in 2 groups were significantly increased, while the levels of vWF and LTBP-2 were significantly decreased (P< 0.05), and the serum indexes in treatment group were significantly better than those in control group (P < 0.05). Conclusion Xinnao Liantong Capsules combined with arolol in treatment of unstable angina pectoris can not only promote the improvement of symptoms, but also promote the improvement of the cytokines and cardiac function, which has a certain clinical application value.

R972

陜西省自然科學(xué)基礎(chǔ)研究計(jì)劃項(xiàng)目（2021JQ-349）